Longevity 2020

Towards a consensus definition of biological aging

Attila Csordas, Founder & Director, AgeCurve Ltd.

Reversal of several aging pathways & diseases

George Church, Founding Core Faculty & Lead, Synthetic Biology, Wyss Institute at Harvard University.

Leveraging aging science (geroscience) to improve older adults’ immune health

Nir Barzilai, Director, Institute for Aging Research.

Connections & differences between different hallmark processes

Lynne Cox, Associate Professor in Biochemistry, University of Oxford.

The use of TORC1 inhibitors to improve immune function in the elderly

Joan Mannick, Chief Medical Officer, resTORbio

How do we show in humans that a drug targets aging?

Nir Barzilai, Director, Institute for Aging Research

Geroprotectors: time to change the way we treat older people?

Ilaria Bellantuono, Professor in Musculoskeletal Ageing, Co-Director, The Healthy Lifespan Institute, Department of Oncology and Metabolism

Interview with Margaretta Colangelo

Margaretta Colangelo, Co-founder / Managing Partner, Deep Knowledge Ventures / Longevity.Capital / Deep Knowledge Analytics

Applying AI approaches to diverse aging-related problems

Alexander Zhavoronkov, Chief Executive Officer, Insilico Medicine, Inc

Margaretta Colangelo in conversation with Richard Siow, John Shepherd, and Alexander Zhavoronkov

Margaretta Colangelo, Co-founder / Managing Partner, Deep Knowledge Ventures / Longevity.Capital / Deep Knowledge Analytics

The Big Picture: Covid-19 and Longevity investing

Jim Mellon, Chairman and Founder, Burnbrae Group

The view from the valley

Kate Batz, Managing Partner, Longevity Capital and Director of Strategy at Deep Knowledge Ventures and Aging Analytics Agency.

Accelerating agetech

Lorraine Morley, UK Lead / Advisor, AgeTech Accelerator

Longevity: Start now … Introduction

Johnny Adams, CEO / Executive Director, Aging Intervention Foundation; Executive Director, Gerontology Research Group

Rejuvant – starting Longevity now

Tom Weldon, Founder, Executive Chairman, Acting CEO, Ponce De Leon Health

How can BioViva address the here and now?

Liz Parrish, CEO, BioViva Sciences

Latest articles

Selfie biomarkers: AI and insurtech implications for Longevity

AI firm Lapetus targets the face as a biomarker of aging: one simple picture can open-up a host of opportunities and implications. Wow. Named after...

Low levels of stress hormone contributes to aging

When it comes to the stress hormone cortisol, balance is everything, according to a new study in Germany.  There have been plenty of studies that...

Rejuvenation Roadmap charts life extension progress

We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress. Lifespan.io is a US-based non-profit organisation that seeks to...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...